Le Lézard
Classified in: Health, Business
Subject: VEN

Omniome Completes $60 Million Series B Financing To Advance Novel Genomic Sequencing Technology


SAN DIEGO, July 30, 2018 /PRNewswire/ -- Omniome, Inc., developer of an innovative new DNA sequencing platform, today announced it has raised an additional $60 million with the completion of its Series B financing.  The funding round was led by Decheng Capital and Hillhouse Capital Group, joined by Lam Research Capital and Nan Fung Life Sciences as well as current investors ARCH Venture Partners, Domain Associates, Biomatics Capital Partners and Altitude Life Science Ventures. 

"We have been able to validate the tremendous power of our proprietary sequencing biochemistry.  Now we are directing our efforts on product development to rapidly advance our first commercial instrument prototypes," said Dave Mullarkey, President and CEO at Omniome. "We appreciate the continued support from our current investors and welcome new investors Decheng Capital, Hillhouse Capital, Lam Research Capital and Nan Fung Life Sciences."

A portion of the proceeds from the financing will be used to expand the company's capabilities by hiring new team members across multiple disciplines, particularly in engineering, and building out additional research and production capacity. The company will continue to optimize the novel Sequencing By Bindingtm (SBBtm) technology while accelerating prototype development of commercially-impactful sequencing platforms.

"Omniome has focused on discovering and developing a novel and differentiated sequencing technology that can further democratize sequencing and broaden its use," said Ken Song, M.D., Omniome's Executive Chairman. "The team has made outstanding progress, and we look forward to working with our investors to bring forth this new sequencing technology system."

About Omniome
Omniome is developing a breakthrough DNA sequencing platform that delivers highly accurate and fast results at low cost with the potential to advance cancer diagnostics, drive high fidelity single-cell applications and broadly support clinical sequencing.  Our scar-free, Sequencing By Bindingtm (SBBtm) technology provides enhanced precision of nucleotide and DNA matching by leveraging the natural matching ability of the polymerase, decreasing runtimes and increasing the number of samples per run.  To learn more about Omniome and our innovative technology, please visit our website at www.omniome.com.

Contact:
Marcy Graham
Corporate Communications
[email protected]
(858) 232-2142

 

SOURCE Omniome, Inc.


These press releases may also interest you

at 13:44
CellFE Inc., a life sciences tools company with a novel microfluidics-based cellular engineering platform, announced today an upcoming presentation by CSO Todd Sulchek, PhD, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting,...

at 13:33
EHN Canada proudly announces a significant regional expansion of EHN Bellwood's legacy in pioneering addiction and mental health treatment centres....

at 13:30
CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners CARBIOS' first plant is also a world first using revolutionary enzymatic depolymerization technology, marking a major step forward in the...

at 13:25
CBL-514 is the first product to treat cellulite at the raised areas.Currently, there is no effective and safe cellulite treatment on the market. The global market for cellulite treatment is estimated to expand to $7.37 billion in 2034.CBL-0201EFP...

at 13:15
The Board of Governors of the Canadian Memorial Chiropractic College (CMCC) is delighted to announce the appointment of Dr. Christine Bradaric-Baus as its next President, effective July 1, 2024, following the retirement of President...

at 13:13
Hoag is proud to announce the recruitment of cancer researchers and subspecialized oncologists Monica Mita, M.D., M.Sc., Mh.D.S., and Alain Mita, M.D., M.Sc., to the Hoag Family Cancer Institute....



News published on and distributed by: